Hitachi Chemical licenses stem cell tech from Israel’s Accellta – גלובס
גלובס |
Hitachi Chemical licenses stem cell tech from Israel's Accellta
גלובס Hitachi Chemical announced its entry into the contracted cell manufacturing market for regenerative medicine in March 2016. In May 2017, Hitachi Chemical completed its acquisition of the US-based company now named Hitachi Chemical Advanced Therapeutics … |
